Cover Image

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Georgio Medawar, Jean‐Sebastien Anoma, Elizabeth Hill, Serena Tharakan, Dahniel L. Sastow, Vincent Lok, Su Bin Hahn, Sarah Chen, Thomas Kehoe, Chidambaram Ramasamy, Julian Guetta‐Weiss, Kapil Meleveedu, Chenyu Lin, David M. Swoboda, Douglas Tremblay, Alexander Coltoff
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
by: Tapan M. Kadia, et al.
Published: (2026)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025)

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
by: Michael K. Jones, et al.
Published: (2026)

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents
by: Ernesto Vigna, et al.
Published: (2025)

Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia
by: Guillaume Berton, et al.
Published: (2025)

Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia
by: Kai Wille, et al.
Published: (2024)

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
by: Somedeb Ball, et al.
Published: (2026)

Venetoclax in Combination With Pediatric‐Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial
by: Yannis K. Valtis, et al.
Published: (2025)

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias
by: Shin‐ichiro Kawaguchi, et al.
Published: (2026)

Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
by: Qingyang Liu, et al.
Published: (2025)

Twenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center
by: Vojtech Latal, et al.
Published: (2026)

KIT V560D‐Mutated Systemic Mastocytosis Associated With High‐Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis–Associated Hematologic Neoplasm
by: Georgio Medawar, et al.
Published: (2024)

Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand
by: Piya Rujkijyanont, et al.
Published: (2026)

Real‐World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia
by: Nehemias Guevara Rodriguez, et al.
Published: (2026)

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
by: Wei‐Ying Jen, et al.
Published: (2025)

A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
by: Tapan M. Kadia, et al.
Published: (2025)

Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
by: Giovanni Marconi, et al.
Published: (2025)

Clinical Experience With Venetoclax‐Based Combinations for Relapsed/Refractory or MRD ‐Positive NPM1 ‐Mutated Acute Myeloid Leukemia
by: Matteo Piccini, et al.
Published: (2026)

Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies
by: Keith W. Pratz, et al.
Published: (2026)

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 DELTA Trial
by: Katja Sockel, et al.
Published: (2025)

Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy
by: Rafael Madero‐Marroquin, et al.
Published: (2025)

Examining Caregiving Burden in Mothers of Children With Newly Diagnosed Leukemia: The Role of Information Needs
by: Hosna Ghorbani, et al.
Published: (2025)

Historia de un r bano pensante : Autobiografía / Peter Medawar ; traducción de Juan José Utrilla
by: Medawar, Peter

The Restructuring of the Portal at the Institut Pasteur Library: A Case Study
by: Medawar, Katia
Published: (2007)

Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study
by: Cassandre Petit, et al.
Published: (2025)

Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview
by: Yufeng Du, et al.
Published: (2025)

Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single‐Center Retrospective Analysis
by: Jason S. Gilbert, et al.
Published: (2025)

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
by: Junyuan Qi, et al.
Published: (2024)

What Is Acute Myeloid Leukemia?
by: Daniel Mazza Matos, et al.
Published: (2025)

Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
by: Marina Konopleva, et al.
Published: (2026)

The Eternal Law
by: Thera, Anoma Muhinda
Published: (1982)

Consejos a un Joven científico / P. B. Medawar ; Traducción de Juan José Utrilla
by: Medawar, P. B
Published: (2011)

Potential Off‐Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild‐Type FLT3 Acute Myeloid Leukemia/Myelodysplastic Neoplasms
by: Shuting Chang, et al.
Published: (2025)

Role of Toll‐Like Receptors in Myeloid Neoplasms: Focuses on the Molecular Mechanisms and Clinical Impact on Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia
by: Clarissa Brenda Alves Cavalcante, et al.
Published: (2025)

Treatment of Chronic Lymphocytic Leukemia (CLL) with Obinutuzumab and Venetoclax: A Case Study
by: Nunes, William Mário de Carvalho, et al.
Published: (2025)

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia
by: Qiuzi Dai, et al.
Published: (2026)

Identification of Potential Biomarkers and Pathways in Acute Myeloid Leukemia: Correlation Between the Calcineurin Signaling Pathway and Vascular Brittleness in Acute Myeloid Leukemia
by: Homood Alharbi, et al.
Published: (2024)

Reciprocal Clonal Dynamics of Independent FLT3 D835V‐Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib
by: Kai Osone, et al.
Published: (2026)

Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia
by: Haoting Chen, et al.
Published: (2024)

Neutrophil/Leukemia‐Tropic Dual‐Drug Nanomedicine Potentiates the Treatment of Acute Myeloid Leukemia
by: Shujing Yue, et al.
Published: (2025)